Meeting
2017 ASCO Annual Meeting
A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010.
Authors
Heather A. Wakelee
Stanford University School of Medicine, Stanford, CA
Heather A. Wakelee , Nasser K. Altorki , Eric Vallieres , Caicun Zhou , Yunxia Zuo , Michael Howland , Fan Xia , Alan Sandler , Enriqueta Felip
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT02486718
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS8576)
DOI
10.1200/JCO.2017.35.15_suppl.TPS8576
Abstract #
TPS8576
Poster Bd #
311b
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.
First Author: Vassiliki Papadimitrakopoulou
Poster
2018 ASCO Annual Meeting
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
First Author: Nathaniel R. Evans
Poster
2017 ASCO Annual Meeting
IMpower132: A phase III clinical program—1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC.
First Author: Howard Jack West
Poster
2023 ASCO Annual Meeting
IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care.
First Author: Martin Reck